Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 13/20 | 0.44 |
| ▸ | STK17B | O94768 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 6/20 | 0.40 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31337606 | 0.95 | BCHE (0.40) | BRD4STK17BSTK17ABCHEACHE | |
| SCHEMBL22445116 | 0.93 | BRD4 (0.46) | BRD4STK17BSTK17A | |
| SCHEMBL31709400 | 0.88 | EGFR (0.42) | BRD4ACHE | |
| SCHEMBL8137366 | 0.87 | BCHE (0.47) | BRD4BCHEACHE | |
| SCHEMBL31709315 | 0.85 | STK17B (0.43) | BRD4STK17BSTK17ABCHEACHE | |
| SCHEMBL8125697 | 0.85 | BCHE (0.47) | BRD4STK17BSTK17ABCHEACHE | |
| SCHEMBL31337610 | 0.85 | STK17B (0.43) | BRD4STK17BSTK17ABCHEACHE | |
| SCHEMBL843596 | 0.81 | BCHE (0.49) | BRD4BCHEACHE | |
| SCHEMBL203530 | 0.80 | STK17B (0.42) | BRD4STK17BSTK17ABCHEACHE | |
| SCHEMBL31709559 | 0.79 | BCHE (0.42) | BRD4STK17BSTK17ABCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| CN-119365479-A | Conjugates comprising Toll-like receptor agonists | 慕宝盛科生物医药(上海)有限公司 | 2025-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | BRD4 1796/4885STK17B 385/4885STK17A 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.